Report Phase 2 proof-of-concept results for encaleret
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 26 Jan 2021
- Due
- 30 Sep 2021
- Delivered
- Q3 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 2 proof-of-concept results are anticipated in the third quarter of 2021.”
What we found
Evidence strength A What the grades mean
The company reported early results from its Phase 2 study of encaleret in 2021, satisfying the commitment to provide proof-of-concept results within the third quarter of 2021.
-
A BridgeBio Pharma, Inc. 10-K filed 2022-02-25
“We reported early results from this study in 2021.” ✓ confirmed on the page
Market reaction: the shares moved +4.1% against the S&P 500 over the three sessions around the disclosure (24 Feb 2022 to 1 Mar 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 2 proof-of-concept results for encaleret
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you BridgeBio Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BBIO-022423 · Corrections policy